SCHEMBL5163433

SCHEMBL5163433

COC(=O)CC(=O)c1cc2ccccc2cn1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 1/20 0.48
NOTUM Q6P988 1/20 0.42
HDAC3 O15379 1/20 0.42
HDAC1 Q13547 1/20 0.42
HDAC2 Q92769 1/20 0.42
USP30 Q70CQ3 1/20 0.41
HTR1A P08908 1/20 0.41
HTR2A P28223 1/20 0.41
HTR2C P28335 1/20 0.41
DRD3 P35462 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2A6 P11509 1/20 0.41
MITF O75030 1/20 0.40
HSP90AA1 P07900 1/20 0.40
HKDC1 Q2TB90 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
HTT P42858 1/20 0.40
KDM4E B2RXH2 2/20 0.40
STAMBP O95630 1/20 0.40
CCNC P24863 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5161426 0.87 GABRP (0.46) EGLN1NOTUMHDAC3HDAC1HDAC2
SCHEMBL5162930 0.85 EGLN1 (0.44) EGLN1NOTUMHDAC3HDAC1HDAC2
SCHEMBL5068303 0.85 KDM4E (0.45) EGLN1NOTUMHDAC3HDAC1HDAC2
SCHEMBL7140246 0.82 EGLN1 (0.58) EGLN1NOTUMHDAC3HDAC1HDAC2
SCHEMBL5162848 0.81 EGLN1 (0.51) EGLN1NOTUMHDAC3HDAC1HDAC2
SCHEMBL5160768 0.81 EGLN1 (0.50) EGLN1NOTUMHDAC3HDAC1HDAC2
SCHEMBL29840564 0.80 LCK (0.56) EGLN1CYP1A2CYP2A6HSP90AA1HTT
SCHEMBL20646994 0.80 EGLN1 (0.49) EGLN1NOTUMHDAC3HDAC1HDAC2
SCHEMBL214090 0.80 LCK (0.56) EGLN1CYP1A2CYP2A6HSP90AA1HTT
SCHEMBL5160560 0.80 EGLN1 (0.47) EGLN1NOTUMHDAC3HDAC1HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293899-B2 Ketone transfer hydrogenation of stereoisomerically enriched 3-heteroaryl-3-oxocarboxylic esters by reducing 3-heteroaryl-3-hydroxycarboxylic esters in the presence of a ruthenium-containing catalyst, an amine and formic acid and/or formates LANXESS DEUTSCHLAND GMBH (DE) 2012-10-23 US disclosed
EP-1340746-B1 Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives SALTIGO GMBH (DE) 2007-02-28 EP disclosed
US-20030225274-A1 Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives LANXESS DEUTSCHLAND GMBH (DE) 2003-12-04 US disclosed
EP-1340746-A1 Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives BAYER AG (DE) 2003-09-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225274-A1 Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives GRHPR, HPD, HAAO EGLN1 3869/4885NOTUM 608/4885HDAC3 123/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.